岩藻糖基化高尔基体蛋白73在小肝癌早期诊断中的价值

赵运胜; 张丽娜; 霍丽静; 裴柳; 李秋平; 李洪臣; 金亮

doi:10.3969/j.issn.1001-5256.2018.08.023

岩藻糖基化高尔基体蛋白73在小肝癌早期诊断中的价值

DOI: 10.3969/j.issn.1001-5256.2018.08.023

1. 秦皇岛市第一医院检验科
2. 河北省人民医院检验科

基金项目:

秦皇岛市科技计划项目(201602A108)；

详细信息

中图分类号: R730.43;R735.7
计量
- 文章访问数: 1399
- HTML全文浏览量: 18
- PDF下载量: 316
- 被引次数: 0
出版历程
- 收稿日期: 2018-02-22
- 出版日期: 2018-08-20

Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

Department of Clinical Laboratory, Qinhuangdao First Hospital

Research funding:

摘要

摘要: 目的探讨血清岩藻糖基化高尔基体蛋白73（Fuc-GP73）在鉴别诊断低浓度AFP原发性小肝癌（s HCC）中的临床价值。方法选取2014年4月-12月秦皇岛市第一医院患者及体检中心健康者共150例,其中低浓度AFP s HCC患者50例（s HCC组）,慢性乙型肝炎患者20例（CHB组）,肝硬化患者20例（LC组）,除肝癌外其他消化系统恶性肿瘤患者20例（MTDS组）,健康对照者40例（NC组）。应用凝集素亲和层析柱联合ELISA法检测血清中Fuc-GP73含量。计量资料多组间比较采用Kruskal-Wallis H检验,进一步两两比较采用Nemenyi检验;计数资料多组间比较采用χ2检验。绘制受试者工作特征曲线（ROC曲线）评价FucGP73检测对s HCC的诊断价值。采用logistic回归分析预测模型评价各标志物联合检测的诊断效果。结果各组Fuc-GP73水平差异有统计学意义（H=87.225,P=0.001）,其中s HCC患者Fuc-GP73水平明显高于其他组（P值均<0.05）;Fuc-GP73在s HCC组、CHB组、LC组、MTDS组和NC组...
- 癌,肝细胞 /
- 高尔基体蛋白73 /
- 糖基化 /
- 早期诊断
Abstract: Objective To investigate the clinical value of serum fucosylated Golgi protein 73 ( Fuc-GP73) in the differential diagnosis of small hepatocellular carcinoma ( s HCC) with a low level of alpha-fetoprotein ( AFP) . Methods A total of 110 patients who were treated in Qinhuangdao First Hospital from April to December, 2014 were enrolled, and among these patients, 50 had s HCC with a low level of AFP ( s HCC group) , 20 had chronic hepatitis B ( CHB group) , 20 had liver cirrhosis ( LC group) , and 20 had malignant tumor in the digestive system except liver cancer ( MTDS group) . A total of 40 individuals who underwent physical examination in our hospital were enrolled as normal controls ( NC group) . Lectin affinity chromatography and ELISA were used to measure the serum level of Fuc-GP73. The Kruskal-Wallis H test was used for comparison of continuous data between multiple groups, and the Nemenyi test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic ( ROC) curve was plotted to analyze the value of Fuc-GP73 in the diagnosis of s HCC. The logistic regression model was used to evaluate the diagnostic efficiency of the combined measurement of Fuc-GP73 and other markers. Results There was a significant difference in the level of Fuc-GP73 between groups ( H = 87. 225, P = 0. 001) , and the s HCC group had a significantly higher level than the other groups ( all P <0. 05) . The detection rate of Fuc-GP73 was 80% ( 40/50) in the s HCC group, 0 ( 0/20) in the CHB group, 20% ( 4/20) in the LC group, 5% ( 1/20) in the MTDS group, and 0 ( 0/40) in the NC group; there was a significant difference between groups ( χ2= 92. 143, P< 0. 01) , and the s HCC group had a significantly higher detection rate than the other groups ( all P < 0. 01) . In the diagnosis of s HCC, Fuc-GP73 had a sensitivity of 80. 0%, a specificity of 95. 0%, an accuracy rate of 90. 0%, and an area under the ROC curve of 0. 892, and the combined measurement of Fuc-GP73 and other markers had a sensitivity of 96. 0%, a specificity of 98. 0%, an accuracy rate of97. 3%, and an area under the ROC curve of 0. 991. Conclusion Fuc-GP73 can be used as a glycosylated tumor marker for s HCC and is better than AFP.
- carcinoma, hepatocellular /
- Golgi protein 73 /
- glycosylation /
- early diagnosis

HTML全文

参考文献(25)

[1] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]CLARK HP, CARSON WF, KAVANAGH PV, et al.Staging and current treatment of hepatocellular carcinoma[J].Radiographics, 2005, 25 (Suppl 1) :s3-s23.

[3]YAMAMOTO K, IMAMURA H, MATSUYAMA Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J].J Gastroenterol, 2010, 45 (12) :1272-1282.

[4]JOHNSON PJ.The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J].Clin Liver Dis, 2001, 5 (1) :145-159.

[5]ZHANG Q, SHAN HL, XU W.Value of serum GP73, AFP, and AFP-L3 in diagnosis of liver cancer and recurrence monitoring after radiofrequency ablation[J].J Clin Hepatol, 2015, 31 (2) :232-235. (in Chinese) 张勤, 单洪丽, 续薇.血清高尔基体糖蛋白73、甲胎蛋白及甲胎蛋白异质体3在肝癌诊断及射频消融术后复发监测中的应用价值[J].临床肝胆病杂志, 2015, 31 (2) :232-235.

[6]MIYOSHI E, MORIWAKI K, NAKAGAWA T.Biological function of fucosylation in cancer biology[J].J Biochem, 2008, 143 (6) :725-729.

[7]WU J, ZHU J, YIN H, et al.Analysis of glycan variation on glycoproteins from serum by the reverse lectin-based ELISA assay[J].J Proteome Res, 2014, 13 (4) :2197-2204.

[8]MA C, ZHANG Q, QU J, et al.A precise approach in large scale core-fucosylated glycoprotein identification with low-and highnormalized collision energy[J].J Proteomics, 2015, 114:61-70.

[9]JIANG K, LI W, ZHANG Q, et al.GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness[J].Oncotarget, 2016, 7 (17) :23530-23541.

[10]JIANG K, SHANG S, LI W, et al.Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases[J].Glycoconj J, 2015, 32 (9) :657-664.

[11]ZHANG S, JIANG K, SUN C, et al.Quantitative analysis of sitespecific N-glycans on sera haptoglobinβchain in liver diseases[J].Acta Biochim Biophys Sin (Shanghai) , 2013, 45 (12) :1021-1029.

[12]WEI FX, LIU Z, GENG J, et al.Research advances in association between Golgi protein 73 and liver diseases[J].J Clin Hepatol, 2017, 33 (8) :1595-1598. (in Chinese) 魏丰贤, 刘钊, 耿婕, 等.高尔基体蛋白73与肝脏疾病的关系[J].临床肝胆病杂志, 2017, 33 (8) :1595-1598.

[13]ZHAO Y, WANG M, CUI C, et al.Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma[J].Cancer Biomark, 2015, 15 (5) :677-683.

[14]BLOCK TM, COMUNALE MA, LOWMAN M, et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J].Proc Natl Acad Sci U S A, 2005, 102 (3) :779-784.

[15]DRAKE RR, SCHWEGLER EE, MALIK G, et al.Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers[J].Mol Cell Proteomics, 2006, 5 (10) :1957-1967.

[16]Chinese Anticancer Association.New standard for diagnosis and treatment of common malignant tumors[M].Beijing:Chinese Union Medical University Press, 1999:389. (in Chinese) 中国抗癌协会.新编常见恶性肿瘤诊治规范[M].北京:中国协和医科大学出版社, 1999:389.

[17]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.

[18] WANG JZ, FAN M.Protein technical manual[M].Beijing:Science Press, 1986:235-243. (in Chinese) 汪家政, 范明.蛋白质技术手册[M].北京:科学出版社, 1986:235-243.

[19]ZHAO YS, WANG M, CUI CY, et al.Clinical significance of eight serum indexes in diagnosis of primary hepatic carcinoma[J].Chongqing Med, 2014, 43 (2) :214-216. (in Chinese) 赵运胜, 王猛, 崔辰莹, 等.评价8种血清标志物在原发性肝癌诊断中的临床价值[J].重庆医学, 2014, 43 (2) :214-216.

[20]YANG SP, LI HY.Diagnostic value of AFP and GP73 test in patients with primary hepatic carcinoma[J].Chongqing Med, 2012, 41 (27) :2880-2882. (in Chinese) 杨收平, 李海英.血清AFP和高尔基体蛋白73联合检测对原发性肝癌的诊断价值[J].重庆医学, 2012, 41 (27) :2880-2882.

[21]SAFFROY R, PHAM P, REFFAS M, et al.New perspectives and strategy research biomarkers for hepatocellular carcinoma[J].Clin Chem Lab Med, 2007, 45 (9) :1169-1179.

[22]WAIDELY E, AL-YUOBI AR, BASHAMMAKH AS, et al.Serum protein biomarkers relevant to hepatocellular carcinoma and their detection[J].Analyst, 2016, 141 (1) :36-44.

[23]OZKAN H, ERDAL H, TUTKAK H, et al.Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J].Digestion, 2011, 83 (1-2) :83-88.

[24]KUZMANOV U, KOSANAM H, DIAMANDIS EP.The sweet and sour of serological glycoprotein tumor biomarker quantification[J].BMC Med, 2013, 11:31.

[25]MATSUMOTO H, SHINZAKI S, NARISADA M, et al.Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer[J].Clin Chem Lab Med, 2010, 48 (4) :505-512.

施引文献

资源附件(0)

访问统计